Progesterone for sleep: distinguish a trial endpoint from a side effect
Oral micronized progesterone has been studied for sleep in small trials, but the current Prometrium label does not include insomnia. Drowsiness on a label is not proof of a durable sleep benefit or a reason to choose a hormone without an individualized review.
Progesterone has a limited, formulation-specific sleep evidence base; it is not FDA-approved as an insomnia treatment. Small randomized studies of oral micronized progesterone reported changes in measured wakefulness or perceived sleep in selected peri- or postmenopausal women. The current Prometrium label instead lists endometrial protection with estrogen in a defined population and secondary amenorrhea. Its drowsiness warning is a safety observation, not an insomnia efficacy claim.123
“I sleep badly” can mean hot-flash awakenings, difficulty falling asleep, frequent waking, unrefreshing sleep, or a possible sleep disorder. A study measuring one of those outcomes should not be used to promise improvement in all of them. The hormone decision also may have a purpose unrelated to sleep, especially protection of the uterine lining during systemic estrogen use.
Sort the evidence by outcome, not by the word sleep
| Evidence item | What it measured | Boundary |
|---|---|---|
| Prometrium prescribing information | Approved indications and adverse effects | Drowsiness does not establish insomnia treatment |
| Small postmenopause sleep-lab crossover study | Polysomnographic sleep and wake measures over a short protocol | Does not establish durable benefit in a broad insomnia population |
| Perimenopause randomized trial | Vasomotor symptoms plus patient-reported sleep and other outcomes | Perceived sleep signal should not be called a proven primary insomnia endpoint |
The 2008 sleep-laboratory study was controlled and therefore more informative than an anecdote, but it was small and short. The 2023 perimenopause trial adds a different population and patient-reported sleep result; its main vasomotor endpoint was not definitive. Neither trial creates an FDA-approved sleep indication or proves that every progesterone route, compound, cream and combination has the same effect.23
The finished product changes the question
Prometrium is an oral micronized progesterone capsule. Its current label includes drowsiness and dizziness and identifies a peanut-oil allergy issue. A compounded capsule or topical cream does not inherit the finished product’s approval, formulation or study results. The cream-versus-oral guide addresses a different question: whether an offered route protects the endometrium when systemic estrogen is used.1
If a clinic cites “bioidentical progesterone for sleep,” ask which exact product, which studied regimen and which sleep endpoint it means. A label can support a product-risk statement; a trial can support a narrow efficacy observation. Neither alone decides an individual’s treatment plan.
Identify the reason for a prescription
For a person with a uterus using systemic estrogen, a progestogen may be discussed for endometrial protection. That purpose needs its own regimen and evidence, even if sleep is also a concern. For someone not using estrogen, “sleep support” is a different proposed use and should be described as such. The progesterone-versus-progestin article separates hormone classes without treating them as interchangeable sedatives.
At a consultation, bring the pattern of sleep difficulty, daytime effects, current medicines and supplements, menopause symptoms, whether estrogen is in the plan, and any prior hormone response. Ask what outcome the clinician expects to change and how it will be assessed. If the answer is only “progesterone makes people sleepy,” it has not yet connected the relevant trial, label and patient’s goal.
The hormone-therapy provider hub can help compare programs on product transparency and follow-up. A useful program explains both the potential sleep evidence and its limits while preserving the separate reason a hormone is prescribed.
Sources
- National Library of Medicine DailyMed. PROMETRIUM (progesterone) capsules current prescribing information. Labeled uses are endometrial-hyperplasia prevention with estrogen in specified women and secondary amenorrhea; drowsiness/dizziness and peanut-oil allergy are label issues, not an insomnia indication. Accessed .
- PubMed / original randomized crossover study. Progesterone and polysomnographic sleep measures in postmenopausal women. Small controlled sleep-laboratory study measured objective wakefulness under a specified progesterone regimen; it does not establish long-term insomnia treatment. Accessed .
- PubMed / original randomized trial. Oral micronized progesterone in perimenopause: symptoms and perceived sleep. Perimenopause trial reported a perceived-sleep signal while its primary vasomotor-symptom result was inconclusive; population and endpoint must stay separate. Accessed .